Filtered By:
Management: Centers for Disease Control and Prevention (CDC)
Vaccination: Vaccines

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 39 results found since Jan 2013.

An Association Between Herpes Zoster Vaccination and Stroke Reduction Among Elderly Individuals.
Authors: Klaric JS, Beltran TA, McClenathan BM Abstract Herpes zoster (HZ, shingles) affects individuals (60+ years) by reactivation of varicella virus from primary infection. Approximately one-third of the general population will develop HZ and are at increased risk of stroke. Our objective was describing possible associations between self-reported HZ vaccination and stroke with the Centers for Disease Control and Prevention's Behavioral Risk Factors Surveillance System, a cross-sectional nationwide telephone survey. Non-institutionalized U.S. adults answered items concerning health risk behaviors. 2014 survey dat...
Source: Military Medicine - March 23, 2019 Category: International Medicine & Public Health Tags: Mil Med Source Type: research

Johnson & Johnson Launches Heartline ™, the First-of-its-Kind, Virtual Study Designed to Explore if a New iPhone App and Apple Watch Can Help Reduce the Risk of Stroke
New Brunswick, NJ, February 25, 2020 — Johnson & Johnson (NYSE: JNJ) today announced that the Janssen Pharmaceutical Companies of Johnson & Johnson, in collaboration with Apple, opened enrollment for the Heartline™ Study. The study is designed to explore if the Heartline™ Study app on iPhone and heart health features on Apple Watch can improve health outcomes, including reducing the risk of stroke, with earlier detection of atrial fibrillation (AFib). AFib, a common form of irregular heart rhythm, is a leading cause of stroke in the U.S. To enroll in the Heartline™ Study, individuals must be age 65 or older...
Source: Johnson and Johnson - February 25, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

CDC Says Stroke Concerns Over Pfizer Jab Warrant Investigation | ZeroHedge
CDC Says Stroke Concerns Over Pfizer Jab Warrant Investigation The Centers for Disease Control and Prevention (CDC) says that data collected on the Pfizer-BioNTech COVID-19 vaccine merits an investigation into potential stroke risks for people aged 65 and older. "Following the availability and use…#cathymcmorrisrodgers #fda #vsd #cdc #strokeconcerns
Source: Reuters: Health - January 15, 2023 Category: Consumer Health News Source Type: news

No Increased Stroke Risk Linked to Pfizer ’s Covid Boosters, Federal Officials Say
An uptick hinted at in surveillance data was a mirage, the officials said.
Source: NYT Health - January 14, 2023 Category: Consumer Health News Authors: Apoorva Mandavilli Tags: your-feed-science Vaccination and Immunization Coronavirus (2019-nCoV) Elderly Stroke Coronavirus Risks and Safety Concerns BioNTech SE Pfizer Inc Centers for Disease Control and Prevention Food and Drug Administration Source Type: news

New Data From Two Large Studies Reinforce Effectiveness of Dual Pathway Inhibition (DPI) with XARELTO ® (rivaroxaban) Plus Aspirin in Patients with Coronary Artery Disease (CAD) and/or Peripheral Artery Disease (PAD)
RARITAN, N.J., May 23, 2022 – Findings from the XARELTO® (rivaroxaban) Phase 3 COMPASS Long-Term Open Label Extension (LTOLE) study and the XARELTO® in Combination with Acetylsalicylic Acid (XATOA) registry have been published in the European Society of Cardiology’s (ESC) European Heart Journal, Cardiovascular Pharmacotherapy. Additionally, the XATOA registry was presented at the American Congress of Cardiology’s 71st Annual Scientific Session (ACC.22). These studies provide further evidence supporting the role of dual pathway inhibition (DPI) with the XARELTO® vascular dose (2.5 mg twice daily plus aspirin 100 mg...
Source: Johnson and Johnson - May 23, 2022 Category: Pharmaceuticals Source Type: news

Landmark Phase 3 VOYAGER PAD Study of XARELTO ® (rivaroxaban) Plus Aspirin Shows Significant Benefit in Patients with Symptomatic Peripheral Artery Disease (PAD) after Lower-Extremity Revascularization
RARITAN, NJ, March 28, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the VOYAGER PAD study met its primary efficacy and principal safety endpoints, demonstrating the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily) plus aspirin (100 mg once daily) was superior to aspirin alone in reducing the risk of major adverse limb and cardiovascular (CV) events by 15 percent in patients with symptomatic peripheral artery disease (PAD) after lower-extremity revascularization, with similar rates of TIMI[1] major bleeding. VOYAGER PAD is the only study to show a significant benefit using...
Source: Johnson and Johnson - March 28, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Submits Application to U.S. FDA for New Indication to Expand Use of XARELTO ® (rivaroxaban) in Patients with Peripheral Artery Disease
RARITAN, NJ, October 26, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for a new indication to expand the use of XARELTO® (rivaroxaban) in patients with peripheral artery disease (PAD). If approved, this new indication for the XARELTO® vascular dose (2.5 mg twice daily plus aspirin 75-100 mg once daily) would include reducing the risk of major thrombotic vascular events such as heart attack, stroke and amputation in patients after recent lower-extremity revascularization, a c...
Source: Johnson and Johnson - October 26, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Real-World Study Confirms Benefit of XARELTO ® (rivaroxaban) for Secondary Prevention of Venous Thromboembolism in Cancer Patients
TITUSVILLE, NJ, December 9, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced observational data from eight years of clinical practice showing that the oral Factor Xa inhibitor XARELTO® (rivaroxaban) is associated with comparable effectiveness and safety to the Factor Xa inhibitor apixaban for the treatment of cancer-associated thromboembolism (CAT) in a broad cohort of patients with various cancer types. Patients with CAT are at a higher risk of venous thromboembolism (VTE), which is the second-leading cause of death in people with cancer.1Data from the Observational Study in Cancer-A...
Source: Johnson and Johnson - December 9, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news

New XARELTO ® (rivaroxaban) Peripheral Artery Disease (PAD) Data from EXPLORER Clinical Research Program to be Unveiled at American Heart Association (AHA) Scientific Sessions 2020
RARITAN, N.J., November 9, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that 10 data presentations will be shared at the virtual American Heart Association (AHA) Scientific Sessions 2020 from November 13-17. Most notably, four new sub-analyses of XARELTO® (rivaroxaban) from the landmark VOYAGER PAD trial, part of the EXPLORER global cardiovascular research program, will be presented, including two live, featured science oral presentations. “We're pleased VOYAGER PAD was selected to be front and center once again at a major medical congress, as there's an urgent need for data in ...
Source: Johnson and Johnson - November 9, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

10 Good Reasons To Get A Flu Shot
By Melaina Juntti for Men's Journal How many times have you heard you should get a flu shot? There's good reason for the hype: Over the past few years, the influenza vaccine has prevented millions of flu cases and tens of thousands of related hospitalizations, according to Centers for Disease Control and Prevention. Although an increasing number of people are getting vaccinated every year, more than half of American men still aren't doing it, for a variety of reasons, most of which aren't backed by science. "Men have this macho sense that if they do get the flu, they can tough it out," says William Schaffner, M.D., chair...
Source: Science - The Huffington Post - November 29, 2014 Category: Science Source Type: news

FDA Experts Vote to Make All COVID-19 Vaccines and Boosters Bivalent
In a unanimous decision, all 21 voting members of the U.S. Food and Drug Administration’s (FDA) vaccine committee recommended that the U.S. start using the same COVID-19 virus strain in all of the COVID-19 vaccines, including primary and booster doses. That means the bivalent booster dose, which targets both the original SARS-CoV-2 strain and the Omicron BA.4/5 strains, would soon become the only type used for all primary shots and boosters. The decision reflects a turning point in the pandemic. Until now, vaccine makers have tried to keep up with constantly evolving variants, but they’ve always been a few step...
Source: TIME: Health - January 27, 2023 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 healthscienceclimate Source Type: news

Madison Small And The Threat Of Bacterial Meningitis
Eighteen-year old high school student Madison Small of Ashburn, Virginia is dead after a swift and unexpected bacterial infection, reported ABC News. Small, an accomplished softball player, complained of a headache on the evening of Monday, Apr. 6 and was taken to the hospital, according to local news station WJLA in the video above. She died the next morning. On April 13, health investigators announced that she had died of bacterial meningitis, but said that her case was not part of a wider outbreak in the community. Bacterial meningitis is rare but severe. The infection, which can be caused by several different strai...
Source: Science - The Huffington Post - April 13, 2015 Category: Science Source Type: news

Mayo Clinic Minute: Cholesterol Vaccine
Watch today's Mayo Clinic Minute High cholesterol increases your risk of heart disease and stroke. The Centers for Disease Control and Prevention reports that more than 73 million Americans have high levels of low-density lipoprotein (LDL), or "bad" cholesterol, and only about half of those people are on proper treatment. Statins are very effective medications for [...]
Source: News from Mayo Clinic - November 20, 2015 Category: Databases & Libraries Source Type: news